CARIBOU BIOSCIENCES INC
NASDAQ: CRBU (Caribou Biosciences, Inc.)
最近更新时间: 15小时之前0.459
0.02 (4.43%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Caribou Biosciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.49 |
|
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 9.83% |
| 机构持股比例 | 53.66% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Pfizer Inc | 30 Jun 2026 | 4,690,431 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 2,503,302 |
投资组合